Replies to post #5810 on IntelGenx Technologies Corp (IGXT)

[kickask]

Doesn't look like it is going to make it but closing above .60 would be very positive

[crookedneck]

Excellent DD JimsZ! IGXT has everything going for them in so many areas and 2012 will spring board them into a GREAT 2013 success imo. Throughout this year we should begin to see all these developments take place and hopefully, as the CEO stated "Acheive profitability in 2012" . I also think this is worth posting regarding what IGXT has in the works, current partnerships, accomplishments, along with what they are currently have in the works right now:

Industry: Bio-technology
Market Capitalization: 24,936,201
Outstanding Shares: 39,581,272
Insider Ownership: 28%
Listing Exchanges: OTCQB as IGXT and Toronto Ventrue Exchange: IGX

We are a unique drug delivery company focused on improving existing medications by incorporating our proprietary,
advanced formulation and manufacturing technologies. We are currently developing products for multiple indications.


Our three proprietary platform technologies include:

Multilayer Tablet Technology, VersaTab, which allows for the development of oral controlled release products
Oral Film Technology, VersaFilm, which allows for the immediate delivery of pharmaceutically active substances to the oral cavity for oral or gastro-intestinal absorption
Mucoadhesive Technology, AdVersa, for either quick or controlled release to control drug delivery absorption kinetics/rates and which offers a means to increase drug permeability


Our current partners include, among others, Azur Pharma, Dava Pharmaceuticals and RedHill Biopharma. We are also in discussions with several other potential partners for some of our other products. Feb 14th Update: IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced that it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC ("Edgemont") for the commercialization of IntelGenx' lead product CPI-300 in the United States (U.S.).

Our unique proprietary platform delivery technologies offer many benefits to our partners including:
Broad range of delivery profiles
Convenient and versatile products
High quality products


Business Strategy
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy.
Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed. As a result, we believe we can accelerate development and reduce risk compared to traditional pharmaceutical and biotechnology companies.

Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining three years of market exclusivity.


JimsZ Feb 14th post:

Another thing to look at here is something that's a little mis-understated is CPI-300 wasn't the ONLY thing going on with IGXT (even though most here have no clue)


Par Pharmaceuticals and the development agreement with them. I can't find any information on value, but I'm sure Par Pharma will pay big $$$ for co-development of a drug using Intelgenx's delivery methods ($$$). It's listed on PRX's 8k, but not stated what IntelGenx has received and/or will receive. This could be HUGE as Par Pharma is a pretty big Pharmaceutical (see NYSE PRX)!

12/16/11 Par Pharma filed a CT filing (Confidential Treatment) - a few days later IGXT comes out with Par Pharma co-development on a drug with terms undisclosed. Is it possible IGXT signed with Edgewater Pharmaceuticals because CPI-300 is small fish compared to the confidential agreement with Par Pharma and CPI-300 as long as it gives "something" is good enough ?


1/6/12 Par Pharma filed an 8k listing IntelGenx as co-developer
See page 43 - IntelGenx Dev Deal for 2011

Per IGXT's 8k regarding PAR Pharmaceuticals on 12/21/11

Item 1.01 Entry Into a Material Definitive Agreement.

On December 19, 2011, IntelGenx Corp., a wholly owned subsidiary of IntelGenx Technologies Corp. (the “Company”), entered into a Development Services and Commercialization Agreement (the “Agreement”) with Par Pharmaceutical, Inc. (“Par”) for the development and commercialization of a new product utilizing one of the Company’s proprietary oral drug delivery platforms.

Under the terms of the Agreement, Par has obtained certain exclusive rights to market and sell the product in the United States. In exchange for granting Par such rights, the Company will receive upfront payments, contingent milestone payments, and a double-digit percentage royalty of all net sales upon commercialization. In addition, Par has a right of first refusal to obtain the exclusive commercialization rights for an additional new product utilizing one of the Company’s proprietary drug delivery platforms.

The term of the agreement is the later of (i) 10 years following the earlier of commercial launch and the first commercial sale of the product; and (ii) the end of the commercial life of the product, unless otherwise terminated in the event of, without limitation (i) failure by either the Company or Par to perform their respective obligations under the Agreement; (ii) if pilot bioequivalency studies are not successful, or (iii) otherwise by mutual consent of the parties. The Agreement also contains customary confidentiality, indemnification and intellectual property protection provisions.

On December 21, 2011, the Company issued a press release announcing entry into the Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.


This is ONLY one... There are many more things going on at IGXT as this will be BIG in 2013 !!